$52MSeries A, 25 August 2025
Emerged from stealth with a $52M Series A to advance its lead asset ART4 for Alagille syndrome.
- Amount
- $52M
- Stage
- Series A
- Announced
- 25 August 2025
- Lead
- Eight Roads
- Other investors
- 3E Bioventures, F-Prime Capital
- Use of funds
- Emerged from stealth with a $52M Series A to advance its lead asset ART4 for Alagille syndrome.
- Checked
- Announced by the company
- Sources
- Arnatar Therapeutics reveals $52M Series A globenewswire.com
Arnatar Therapeutics reveals $52M Series A techstartups.com